NAV-006 is a next-generation rituximab. We have discovered that rituximab is bound and immunosuppressed by HIO-1 (CA125) produced in the tumor microenvironment. With this knowledge, we generated NAV-006 by using our Block-Removed Immunoglobulin Technology or BRITE. The BRITE enhancement removes the HIO-1 (CA125) binding site so that NAV-006 is more effective than rituximab at killing lymphoma cells. NAV-006 is being developed for treating HIO-1-positive Non-Hodgkin’s Lymphoma.